What is the Glaukos Corporation stock price forecast?

Glaukos Corporation is currently trading at $127.53. View real-time AI analysis on Alpha Lenz.

What is Glaukos Corporation insider trading activity?

View the latest insider trading data for Glaukos Corporation on Alpha Lenz.

What is Glaukos Corporation's P/E ratio?

Glaukos Corporation's P/E ratio is -38.9.

Glaukos Corporation

NYSE · GKOS

$127.53-2.61(-2.01%)Pre-market

Ask about Glaukos Corporation's future dividend policy...

Alpha Chat Insight

“Glaukos Corporation trades at a P/E of -38.9 (undervalued) with modest ROE of -26.4%. 3Y revenue CAGR of 21.5% highlights clear growth momentum.”

Ask for details →

Company Overview

Glaukos Corporation is a medical technology company dedicated to the development and commercialization of innovative products for the treatment of glaucoma, corneal disorders, and retinal diseases. Its primary function is to address the substantial unmet medical needs present in ophthalmic healthcare. Glaukos is particularly recognized for pioneering novel micro-invasive glaucoma surgery (MIGS) devices, which are designed to reduce intraocular pressure in glaucoma patients through minimally invasive techniques. The company's product portfolio includes various implantable devices and surgical systems, offering alternatives to traditional invasive surgery and medication. Glaukos Corporation significantly impacts the healthcare industry, especially the ophthalmology sector, by providing solutions that improve patient outcomes and quality of life. Its innovations are crucial in the market, as glaucoma remains one of the leading causes of irreversible blindness globally. By focusing on clinically proven products and expanding its technological reach, Glaukos plays a transformative role in enhancing therapeutic standards and contributing to greater accessibility of advanced eye care treatments.

CEOMr. Thomas William Burns

Websitehttps://www.glaukos.com

SectorHealthcare

IndustryMedical Devices

Employees995

Company Statistics

FY 2025

Profile

$7.29BMarket Cap

$507.44MRevenue

0.00Shares Out

995Employees

Margins

55.72%Gross

-28.78%EBITDA

-39.33%Operating

-38.04%Pre-Tax

-36.99%Net

Valuation

-38.86P/E

11.12P/B

14.37EV/Sales

-50.02EV/EBITDA

-186.71P/FCF

Growth (CAGR)

21.51%Rev 3Yr

17.67%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-20.09%ROA

-26.38%ROE

-20.17%ROIC

Financial Health

$90.81MCash & Cash Equivalents

$146.52MNet Debt

36.17%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Glaukos Corporation trades at a P/E of -38.9 (undervalued) with modest ROE of -26.4%. 3Y revenue CAGR of 21.5% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Glaukos Corporation (ticker: GKOS) is a company listed on NYSE in the Healthcare sector (Medical Devices). It has approximately 995 employees. Market cap is $7.3B.

The current price is $127.53 with a P/E ratio of -38.86x and P/B of 11.12x.

ROE is -26.38% and operating margin is -39.33%. Annual revenue is $507M.